Giath Shari, MD
Critical Care Medicine · Monroeville, PANPI 1487789384
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 77.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,292 and has fallen 87.2% since, to $551 in 2025.
Across 37 payments — averaging $150.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$525
- GSK$196
- Galvanize Therapeutics, Inc$190
- Vifor Pharma, Inc.$122
- Novo Nordisk$119
- plus $108 from 5 others
What the payments were for
- Travel & lodging$1,37425%
- Food & beverage$1,60929%
- Education$2,57046%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $4,293 |
| AstraZeneca | 5 | $525 |
| GSK | 7 | $196 |
| Galvanize Therapeutics, Inc | 5 | $190 |
| Vifor Pharma, Inc. | 1 | $122 |
| Novo Nordisk | 1 | $119 |
| Genentech USA, Inc. | 1 | $40 |
| Ceribell, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $18 |
| Insmed, Inc. | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,180
- Veltassa$122
- TRELEGY ELLIPTA$121
- Ozempic$119
- CALQUENCE$111
- ALIYA SYSTEM$106
How this compares
$5,554 in reported general payments places this provider in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 358 | $289,133 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 185 | $99,315 |
| Dupixent SyringeDupilumab | 27 | $95,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 189 | $93,959 |
| Breo ElliptaFluticasone/Vilanterol | 122 | $60,714 |
| Spiriva RespimatTiotropium Bromide | 76 | $52,408 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $27,025 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 83 | $19,183 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $11,016 |
| Tiotropium Bromide | 21 | $8,470 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,203 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $8,187 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 194 | $5,748 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $5,406 |
| Roflumilast | 25 | $3,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $196 | $454,822684 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $525 | $40,61874 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Monroeville
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Robert KruklitisAllentown$148K
- Lisa RathmanLancaster$86K
- Kees PoldermanPittsburgh$85K
- Pavan ThanguduHarrisburg$78K
- David DibardinoPhiladelphia$63K
- Harold PalevskyPhiladelphia$55K
- Steven KawutPhiladelphia$34K
- Michael RisbanoPittsburgh$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.